MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
GTBP — GT Biopharma Inc. Common Stock
NasdaqGT Biopharma Inc. Common Stock
$6.10
-0.10(-1.61%)
- O
- 6.36
- H
- 6.51
- L
- 6.00
- V
- 62.1K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About GTBP
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateFeb 11, 2021
Employees1
Stock ExchangeNasdaq
Ticker SymbolGTBP
Websitehttps://www.gtbiopharma.com
Key Financial Statistics
| Market Cap | $11.01M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $0.25 - $11.98 |
| 52-Week Avg Volume | 1.39M |
| VWAP | $6.22 |
| Transactions | 981 |
| Total Recorded Bars | 2,145 days |